FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Explore this paper's citation graph
Summary
FOLFIRINOX was associated with a survival advantage and had increased toxicity as compared with gemcitabine, and is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.
- Type
- article
- Published
- 2011-05-11
- Cited by
- 6,810
- References
- 38
- Access
- Open access
- OpenAlex
- https://openalex.org/W2151253787
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13591832
Keywords
FOLFIRINOX, Gemcitabine, Irinotecan, Oxaliplatin, Medicine
References
- Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Interpreting the significance of changes in health-related quality-of-life scores.
- Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
- Testing for qualitative interactions between treatment effects and patient subsets.
- Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity
- Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.
- A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer
- Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
- EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.
- Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
- Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
- Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
- Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.
- Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts
- New guidelines to evaluate the response to treatment in solid tumors
- An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Cited by
- Tumeurs de la tête du pancréas : un défi diagnostique et thérapeutique à Ouagadougou
- Maligne Erkrankungen des Gastrointestinaltrakts bei alten Patienten
- Pancreatic cancer: current standards, research updates and future directions.
- Pancreatic Cancer Experimental and Clinical Studies
- Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials
- Japan Pancreatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society
- Understanding pancreatic cancer genomes
- Biomarkers for pancreatic cancer: is it ready for primetime?
- Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
- Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
- Outpatient Advance Care Planning for Patients with Metastatic Cancer: A Pilot Quality Improvement Initiative
- Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
- Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX
- Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
- Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells
- Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors
- Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.
- Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention
- Early decrement of serum carbohydrate antigen 19‐9 predicts favorable outcome in advanced pancreatic cancer
- Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis
Related papers
- FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study
- FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study).
- Treatment of Advanced Pancreatic Cancer with Combination of Gemcitabine and Oxaliplatin
- Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine
- Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.
- [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
- Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.
- The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients
- Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
- Increased response of oxaliplatin or irinotecan on in vitro chemosensitivity to 5-fluorouracil in patients with colorectal cancer